化合物AKT inhibitor VIII T3346

Product Introduction
Bioactivity


英文名: AKT inhibitor VIII

描述: AKT inhibitor VIII (AKTi-1/2) 是一种细胞渗透的喹喔啉化合物，可逆的选择性抑制Akt1、Akt2和Akt3的活性，IC50值分别为 58 nM、210 nM 和 2119 nM。

细胞实验: The cell growth inhibitory effect of AKTi-1/2 is studied using the 96 h sulforhodamine B assay (SRB). Drug concentrations that inhibited 50% of cell growth (IC50) are calculated for each compound in GraphPad Prism 6.0 using non-linear regression analysis and sigmoidal dose–response (variable slope) equation.(Only for Reference)

激酶实验: Kinase screen: Briefly, all assays (25.5 μl at 21°C for 30 min) are performed using a Biomek 2000 Laboratory Automation Workstation in a 96-well format. Reactions contains 5–20 mU purified kinase along with substrate peptide or protein and are initiated by the addition of 10 mM MgAcetate and 5, 20, or 50 μM ATP ([γ-33P]-ATP, 800 cpm/pmol).

体外活性: Akti-1/2 (50 mg/kg,i.p.)抑制小鼠肺中基底和IGF-刺激的Akt1/2磷酸化作用.

体内活性: 在基于细胞的IPKA (C33A)试验中,AKT inhibitor VIII可抑制Akt1/2（IC50：305/2086 nM）。在MCF7,HT29和A2780细胞中,AKT inhibitor VIII可使caspase-3活性急剧增加从而诱导细胞凋亡。在肝细胞中,AKT inhibitor VIII可阻断胰岛素对PEPCK的调节,以及G6Pase表达和FOXO1活性。AKT inhibitor VIII通过阻断PKB还可使PAR-1-介导的血小板聚集显著增强。在HCC827,NCI-H522,NCI-1651和PC-9细胞中,AKT inhibitor VIII抑制细胞生长（IC50：4.7/7.25/9.5 μM）,AKT inhibitor VIII与gefitinib联用会增强对细胞生长和凋亡的抑制。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 11 mg/mL (20 mM)


关键字: PKB | Inhibitor | AKT inhibitor VIII | Akt | Apoptosis | Protein kinase B | inhibit

相关产品: Anticancer agent 136 | Nirogacestat | Fludarabine | Sophoraflavanone G | Simmiparib | LDC000067 | ARS-853 | MARK4 inhibitor 1 | Antitumor agent-110 | Sanguinarine

相关库: Antioxidant Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Liver Cancer Compound Library | Anti-Metabolism Disease Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Colorectal Cancer Compound Library | Highly Selective Inhibitor Library | Glycolysis Compound Library | Bioactive Compound Library

化合物AKT inhibitor VIII T3346信息由TargetMol中国为您提供，如您想了解更多关于化合物AKT inhibitor VIII T3346报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途